Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;109(1):104-109.
doi: 10.1007/s00223-021-00822-7. Epub 2021 Feb 22.

Hepatitis C-Associated Osteosclerosis: Improvement After Treatment with Sofosbuvir, Daclatasvir, and Ibandronate: Case Report and Literature Review

Maria Carolina de Camargo Vieira  1   2 , Wagner Rodrigo Brida Gonçalves  3 , Ricardo Ayello Guerra  3   4 , Fabiana Siroma Callegaro  5 , Marise Lazaretti-Castro  6 , Sergio Setsuo Maeda  6
Affiliations
Review

Hepatitis C-Associated Osteosclerosis: Improvement After Treatment with Sofosbuvir, Daclatasvir, and Ibandronate: Case Report and Literature Review

Maria Carolina de Camargo Vieira et al. Calcif Tissue Int. 2021 Jul.

Abstract

Hepatitis C-associated osteosclerosis (HCAO) remains a rare condition despite the growing prevalence of hepatitis C virus (HCV) infection worldwide. Since the first case reported in 1992, this is the twenty-second case described. Patients with HCAO present with severe bone pain and elevated serum levels of bone markers, especially alkaline phosphatase (ALP), with increased bone density. We report here the case of a 59-year-old man with generalized bone pain and diagnosis of HCV infection. Biochemical tests showed elevated bone turnover markers, specifically, ALP, carboxy-terminal collagen crosslinks and osteocalcin. Imaging studies revealed generalized bone sclerosis. Bone mineral density was elevated in all validated sites. His clinical symptoms and bone-related findings were attributed to HCAO. He was sequentially treated with cholecalciferol, prednisone, sofosbuvir associated with daclatasvir and ibandronate, and progressed with undetectable viral load after HCV treatment, normalization of ALP levels after introduction of ibandronate, and pain improvement 1 year after discontinuation of the bisphosphonate. Bone pain complaints must be investigated in patients with HCV. HCAO is a differential diagnosis of increased bone mass.

Keywords: Alkaline phosphatase; Case report; Daclatasvir; Hepatitis C-associated osteosclerosis (HCAO); Ibandronate; Sofosbuvir.

PubMed Disclaimer

References

    1. Villareal DT, Murphy WA, Teitelbaum SL, Arens MQ, Whyte MP (1992) Painful diffuse osteosclerosis after intravenous drug abuse. Am J Med 93:371–381. https://doi.org/10.1016/0002-9343(92)90165-8 - DOI - PubMed
    1. Diamond T, Depczynski B (1996) Acquired osteosclerosis associated with intravenous drug use and hepatitis C infection. Bone 19:679–683. https://doi.org/10.1016/s8756-3282(96)00304-3 - DOI - PubMed
    1. Whyte MP, Teitelbaum SL, Reinus WR (1996) Doubling skeletal mass during adult life: the syndrome of diffuse osteosclerosis after intravenous drug abuse. J Bone Miner Res 11:554–558. https://doi.org/10.1002/jbmr.5650110417] - DOI - PubMed
    1. Bergman D, Einhorn TI, Forster G (1996) Stone bone syndrome–diffuse sclerosis of bone: a newly described clinical disorder. EndocrPract 2:296–296. https://doi.org/10.4158/EP.2.4.296 - DOI
    1. Whyte MP, Reasner CA (1997) Hepatitis C-associated osteosclerosis after blood transfusion. Am J Med 102:219–220. https://doi.org/10.1016/s0002-9343(97)89507-1] - DOI - PubMed

LinkOut - more resources